PROCEPT BioRobotics Reports Strong 37% Revenue Growth, Improved Margins, and Key Reimbursement Upgrade in 2025 Annual Report
PRCT sits 22% above its 52-week low of $19.35 on elevated volume (6.4× avg).
Summary
PROCEPT BioRobotics reported strong 37% revenue growth and improved gross margins for fiscal year 2025, alongside a significant upgrade to a Category I CPT code for its Aquablation therapy, enhancing future reimbursement prospects despite continued net losses.
Key Events · Earnings and Guidance · PRCT
-
Strong Full-Year Revenue Growth
The company reported $308.1 million in revenue for fiscal year 2025, representing a substantial 37% increase compared to $224.5 million in 2024.
-
Improved Gross Margin
Gross margin increased to 64% in 2025, up from 61% in 2024, indicating enhanced operational efficiency and scale.
-
Continued Net Losses
PROCEPT BioRobotics incurred a net loss of $95.6 million in 2025, a slight increase from $91.4 million in 2024, as the company continues to invest in growth and development.
-
Significant Reimbursement Upgrade
Aquablation therapy was assigned a new Category I CPT code (52597), effective January 1, 2026, replacing the prior Category III code. This is a major positive for future reimbursement and broader market acceptance.
Analysis · PRCT · Industrial Applications And Services
PROCEPT BioRobotics' 2025 annual report confirms robust operational performance with significant revenue growth and improved gross margins. The upgrade of Aquablation therapy to a Category I CPT code, effective January 1, 2026, is a critical development that is expected to substantially enhance future reimbursement and market adoption. While the company continues to incur net losses, this is typical for a growth-stage medical technology firm, and the reported liquidity provides sufficient runway for the next 12 months. This filing provides the audited details following the preliminary Q4 and full-year results likely announced in a recent 8-K, and reinforces the strategic direction discussed at the Investor Day.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PRCT was trading at $23.63 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $19.35 to $70.80. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.